APM Aptorum Group Limited Stock Quote

APM [NASD]

Healthcare | Biotechnology | United Kingdom

Index	-	P/E	-	EPS (ttm)	-0.72	Insider Own	31.67%	Shs Outstand	35.79M	Perf Week	2.80%
Market Cap	41.62M	Forward P/E	-	EPS next Y	-0.71	Insider Trans	0.00%	Shs Float	9.12M	Perf Month	-10.32%
Income	-25.00M	PEG	-	EPS next Q	-	Inst Own	4.30%	Short Float	1.12%	Perf Quarter	-22.54%
Sales	1.50M	P/S	27.75	EPS this Y	-457.20%	Inst Trans	-8.70%	Short Ratio	0.86	Perf Half Y	-40.86%
Book/sh	0.66	P/B	1.67	EPS next Y	-	ROA	-82.70%	Target Price	15.00	Perf Year	-60.14%
Cash/sh	0.22	P/C	5.01	EPS next 5Y	-	ROE	-85.80%	52W Range	0.86 - 3.50	Perf YTD	-26.67%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-81.10%	52W High	-68.57%	Beta	0.11
Dividend %	-	Quick Ratio	2.90	Sales past 5Y	-	Gross Margin	5.30%	52W Low	28.61%	ATR	0.12
Employees	26	Current Ratio	2.90	Sales Q/Q	200.00%	Oper. Margin	-	RSI (14)	47.47	Volatility	9.31% 13.23%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	24.20%	Profit Margin	-	Rel Volume	2.00	Prev Close	1.05
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	118.61K	Price	1.10
Recom	2.00	SMA20	6.31%	SMA50	-14.90%	SMA200	-41.74%	Volume	237,460	Change	4.76%

May-17-22 08:13AM	Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 26 2022 Business Wire +5.71%
May-09-22 11:41AM	Here's Why We're Watching Aptorum Group's (NASDAQ:APM) Cash Burn Situation Simply Wall St.
May-02-22 08:00AM	Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma Business Wire
Apr-29-22 04:00PM	Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update Business Wire
Apr-25-22 09:30AM	First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted Business Wire -9.86%
Apr-22-22 08:00AM	Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report® Business Wire
Apr-06-22 07:00AM	Andean Precious Metals Announces RSU Grant Newsfile
Mar-22-22 05:58PM	Is Andean Precious Metals Corp.'s (CVE:APM) 4.2% ROE Worse Than Average? Simply Wall St.
Mar-17-22 07:00AM	Andean Precious Metals Reports 2021 Earnings; Delivers on Silver Production and Cost Guidance Newsfile
Jan-25-22 10:06AM	SDC Stock Alert: What Has SmileDirectClub Investors Grinning Ear to Ear Today InvestorPlace +38.89%
08:21AM	APM Stock Alert: What Is Going on With Little-Known Aptorum Today? InvestorPlace
07:45AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday InvestorPlace
Jan-20-22 08:47AM	Aptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer Benzinga +38.52%
08:00AM	Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma Business Wire
Jan-18-22 08:00AM	Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma Business Wire
Jan-11-22 04:56AM	Aptorum Group (NASDAQ:APM) investors are sitting on a loss of 90% if they invested three years ago Simply Wall St.
Jan-10-22 08:00AM	Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology Business Wire
08:00AM	Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers Business Wire
08:00AM	Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma Business Wire
Dec-03-21 08:00AM	Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders Business Wire
Oct-19-21 08:00AM	Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021 Business Wire -5.30%
Oct-15-21 08:00AM	Aptorum Group Limited Interview to Air on Bloomberg U.S. Business Wire
Sep-15-21 09:26AM	Aptorum To Start Testing SACT-1 In Neuroblastoma Patients Benzinga +5.32%
08:00AM	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021 Business Wire
08:00AM	Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma Business Wire
Aug-03-21 03:01PM	Blue Apron CEO on earnings: What we saw in Q2 was actually very expected Yahoo Finance Video
Jul-15-21 02:03AM	What Kind Of Shareholders Hold The Majority In Aptorum Group Limited's (NASDAQ:APM) Shares? Simply Wall St.
Jul-12-21 08:59AM	Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate Benzinga
08:00AM	Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus Business Wire
Jul-09-21 08:00AM	Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report Business Wire
Jun-22-21 04:00PM	Commvault Named 2021 HPE GreenLake Momentum Partner of the Year PR Newswire
Jun-21-21 08:30AM	GigaOm Radar Reports Name Commvault a "Leader" and "Outperformer" for Hybrid Cloud Data Protection in Enterprise and SMB Categories; Commvault Rated Top Performer Across All Categories in Both Reports PR Newswire
May-26-21 08:00AM	Aptorum Group CEO Subscribed Shares In The Company Business Wire +5.34%
May-24-21 12:03PM	Verastem's VS-6766/Defactinib Combo Gets Breakthrough Therapy Tag For Ovarian Cancer; BTIG Upgrades Stock Benzinga +17.65%
11:57AM	Aptorum's Shares Jump After ALS-4 Targeting Staphylococcus Aureus Shows Encouraging Action In Early-Stage Study Benzinga
08:00AM	Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma Business Wire
May-13-21 07:00AM	Aptorum Group Limited to Present at The Benzinga Global Small Cap Conference Business Wire
May-06-21 07:00AM	Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorums Novel Preclinical Candidate Targeting Womans Gynecological Conditions Business Wire
Apr-23-21 11:35AM	Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report. Business Wire
Apr-22-21 09:04AM	Aptorum Shares Are Trading Higher On Immunomodulators Agreement For Autoimmune, Oncology Indications Benzinga
07:00AM	Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases Business Wire
Apr-19-21 07:00AM	Aptorum Group Limited Reports 2020 Fiscal Year End Financial Results and Provides Business Update Business Wire
Mar-31-21 07:00AM	Aptorum Group Announces Dosing First Human Subject in a Phase I Clinical Trial of ALS-4, a First-in-Class Small Molecule Drug Designed to Treat Infections caused by Staphylococcus Aureus including Methicillin-resistant Staphylococcus aureus (MRSA) Business Wire
Jan-20-21 07:32AM	The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga +26.42%
06:00AM	Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA) Business Wire
Jan-16-21 01:23AM	Could The Aptorum Group Limited (NASDAQ:APM) Ownership Structure Tell Us Something Useful? Simply Wall St.
Dec-21-20 06:00AM	Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA) Business Wire
Dec-10-20 08:00AM	Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders Business Wire
Oct-16-20 08:00AM	Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020 Business Wire
Oct-02-20 04:05PM	Aptorum Group Announces Closing of $9.0 Million Public Offering Business Wire -10.73%
Sep-29-20 09:00PM	Aptorum Group Announces Pricing of $9.0 Million Public Offering Business Wire +290.16%
06:00AM	Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome Business Wire
Sep-08-20 03:00AM	Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10 Business Wire
02:00AM	Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance Business Wire
Sep-02-20 08:00AM	Aptorum Group Announces Video Update Discussing Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types Business Wire -13.17%
Sep-01-20 02:00AM	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020 Business Wire
02:00AM	Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types Business Wire
02:00AM	Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models Business Wire
Aug-31-20 06:05PM	LD Micro: 360 Companies Set to Present this Week ACCESSWIRE
Aug-26-20 03:00AM	Aptorum Group Limited to Present at The LD 500 Virtual Conference ACCESSWIRE +6.05%
02:00AM	Aptorum Group Limited to Present at The LD 500 Virtual Conference and H.C. Wainwright 22nd Annual Global Life Sciences Conference Business Wire
Aug-20-20 02:00AM	Aptorum Group Appoints Dr. Herman Weiss as CEO of microbiome-based platform Claves Life Sciences and Dr. Robbie Majzner as scientific advisor to SACT-1 drug for Neuroblastoma and others Business Wire
Aug-05-20 11:04AM	LD Micro Announces Preliminary List of Presenters for the LD-500. ACCESSWIRE
Jul-24-20 02:00AM	Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM Business Wire
Jul-17-20 06:20AM	Aptorum Group Prospectus Receives Approval for Listing on the Euronext Paris Stock Exchange Business Wire +7.56%
Jul-03-20 12:56PM	Here's What Aptorum Group Limited's (NASDAQ:APM) Shareholder Ownership Structure Looks Like Simply Wall St.
Jun-25-20 11:25AM	Analysts Recommend Catching These 2 Falling Knives GuruFocus.com -8.82%
Jun-15-20 08:00AM	Aptorum Group Limited Strengthens Its Presence in the US With the Appointment of Dr. Kira Sheinerman Business Wire +11.73%
Apr-29-20 08:00AM	Aptorum Group Limited to Present at the Infectious Disease Virtual Conference Business Wire +6.76%
08:00AM	Aptorum Group Limited Reports 2019 Fiscal Year End Financial Results and Provides Business Update Business Wire
Apr-15-20 08:00AM	Aptorum Group Limited to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020 ACCESSWIRE
Mar-30-20 08:00AM	Aptorum Group Limited to Present at the Solebury Trout Virtual Investor Conference Business Wire +7.50%
08:00AM	Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress Business Wire
08:00AM	Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT Platform and Acticule Infectious Disease Platform Business Wire
Mar-24-20 04:00PM	Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies ACCESSWIRE
Feb-28-20 01:00PM	Aptorum Group Announces Closing of $10 Million Registered Direct Offering of Class A Ordinary Shares and Warrants Business Wire
Feb-26-20 09:15AM	Aptorum Group Announces Pricing of $10 Million Registered Direct Offering Business Wire -53.47%
Feb-24-20 06:00AM	Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong Business Wire
Feb-10-20 08:00AM	Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020 Business Wire +8.08%
08:00AM	Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track Targeted For IND Submission in H2 2020 Business Wire
Jan-03-20 05:38AM	Did You Manage To Avoid Aptorum Group's (NASDAQ:APM) 13% Share Price Drop? Simply Wall St. +7.83%
Nov-15-19 08:00AM	Aptorum Group Limited Announces Results of 2019 Annual General Meeting Business Wire
Sep-19-19 08:10AM	Aptorum Group Limited's (NASDAQ:APM) Single Biggest Risk For Investors Simply Wall St.
Sep-09-19 06:34AM	Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma Business Wire
06:00AM	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2019 Business Wire
06:00AM	Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA Business Wire
Jul-11-19 08:00AM	Smart Pharma Token (SMPT) Debuts Its Initial Listing On IDAX: Global Blockchain Cryptocurrencies Trading Exchange Platform Business Wire
Jul-08-19 08:00AM	Aptorum Groups subsidiary Smart Pharma announces Smart Pharma token (SMPT) to be listed on IDAX and LATOKEN Business Wire
Jun-26-19 11:05AM	APM: Aptorum Focused on Development of Diseases with Significant Global Unmet Needs Zacks Small Cap Research
May-22-19 08:00AM	Aptorum Group to Be Newly Added to MSCI HK Micro Cap Index Business Wire
May-15-19 09:00PM	Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co-Working Laboratory Ecosystems for Life Sciences Start-Ups in the United States Business Wire
May-07-19 07:19AM	What Percentage Of Aptorum Group Limited (NASDAQ:APM) Shares Do Insiders Own? Simply Wall St.
May-06-19 08:00AM	Aptorum Groups Subsidiary - Claves Life Sciences Limited Establishes Novel Therapeutic Platform for Treatment of Various Diseases via Modulation of the Chemical Signaling Relating to Gut Microbiota Business Wire
Apr-30-19 10:42AM	UPDATE - Argus Research Initiates Equity Research Report Coverage on Aptorum Group Limited (NasdaqGM: APM) GlobeNewswire
Apr-24-19 08:00AM	USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations Business Wire
04:30AM	Aptorum Groups Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT Business Wire
04:30AM	Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases Business Wire
04:15AM	Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 2019 Business Wire
Apr-15-19 09:55AM	Aptorum Group Limited Reports 2018 Fiscal Year Financial Results and Business Update Business Wire
Apr-01-19 09:30AM	Aptorum Group Limited Announces Appointment of Head of R&D and Chief Operating Officer Business Wire

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience